Two psychosocial treatments and three drug treatments for cocaine dependence will be compared in a random assignment study, over a four week treatment period. The psychosocial treatments compared will be a one month 15 hour a week day hospital or a six hours, three times a week outpatient program. The drug conditions will be 300 mg daily of amantadine hydrochloride, 300 mg. daily of placebo, or a nonmedication condition. The drug trial will be conducted double blind. Two hundred and forty (240) cocaine dependent men will be studied, 40 in each of the six treatment conditions. Subjects will be followed over a two year period. One half of the subjects will be followed every two months during the first year and every three months in the second year; while the remaining subjects will be followed every six months for two years. A baseline assessment battery will measure psychopathology, risk for AIDS behavior, cocaine and alcohol use, substance abuse related problems, social support, abstinence commitment, moods, and self efficacy. Some of these measures will also be re-evaluated during some of the followup evaluations. Costs during the two year study period will also be ascertained. In study years 3, 4, and 5 promising drugs will be studied in double blind, placebo controlled fashion. This study will provide critical information concerning the efficacy and cost effectiveness of two forms of psychosocial treatment for cocaine dependence. It will also yield important information about the effectiveness of amantadine hydrochloride under two levels of psychosocial treatment. Subsequent drug trials will benefit from the study findings by being able to use the minimal psychosocial treatment found to be effective in the initial study. The study will provide important detailed information about the course of response to treatment for cocaine dependence over a two year followup period. Predictors of favorable treatment response will also be ascertained.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Comprehensive Center (P60)
Project #
5P60DA005186-11
Application #
2665355
Study Section
Project Start
Project End
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Franklin, Teresa R; Jagannathan, Kanchana; Hager, Nathan et al. (2018) Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. Drug Alcohol Depend 182:78-85
Wetherill, Reagan R; Jagannathan, Kanchana; Hager, Nathan et al. (2016) Influence of menstrual cycle phase on resting-state functional connectivity in naturally cycling, cigarette-dependent women. Biol Sex Differ 7:24
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Van Horn, Deborah H A; Drapkin, Michelle; Lynch, Kevin G et al. (2015) Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment. Addict Res Theory 23:391-403
Franklin, Teresa R; Jagannathan, Kanchana; Wetherill, Reagan R et al. (2015) Influence of menstrual cycle phase on neural and craving responses to appetitive smoking cues in naturally cycling females. Nicotine Tob Res 17:390-7
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Goldman, Marina; Ehrman, Ronald N; Suh, Jesse J et al. (2015) Brief report: ""spiders-No, puppies-Go"", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. J Adolesc 38:45-8
McKay, James R; Drapkin, Michelle L; Van Horn, Deborah H A et al. (2015) Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol and cocaine dependence. J Consult Clin Psychol 83:1021-32
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N et al. (2014) The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 78:33-9

Showing the most recent 10 out of 111 publications